THU0154 Biomarker Sets PREDICT Therapeutic Response to Tnf-Inhibitors in Rheumatoid Arthritis and Spondyloarthritis Patients: A Theragnostic Approach in A Multicenter Cohort

• Published in: Annals of the rheumatic diseases Vol. 73; no. Suppl 2; p. 233
• Main Authors: Baillet, A., Trocmé, C., Marotte, H., Soubrier, M., Tébib, J., Thomas, T., Miossec, P., Pellot-Prades, B., Grange, L., Toussaint, B., Juvin, R., Morel, F., Drouet, C., Gaudin, P.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2014

Background TNF inhibitors (TNFi) are first-line treatments for patients suffering from rheumatoid arthritis (RA) and spondyloarthritis (SpA). However, it is currently impossible to predict response to Infliximab (IFX), Adalimumab (ADA) or Etanercept (ETN). Objectives To predict response to IFX, ADA...